Vol. 2, No. 3; Jul – Sep (2023)

Quing: International Journal of Innovative Research in Science and Engineering

Available at https://quingpublications.com/journals/index.php/ijirse/index

Nanotechnology in the Fight Against Superbugs: Targeting Drug-Resistant Bacteria with Nanomachines

Ruban P*

Assistant Professor, Department of Biotechnology and Research, Shri Nehru Maha Vidyalaya College of Arts and Science, Coimbatore, TN, IND.

Vinitha Ebziba C

Assistant Professor, Department of Biotechnology and Research, Shri Nehru Maha Vidyalaya College of Arts and Science, Coimbatore, TN, IND.

ARTICLE INFO

Received: 08-07-2023
Received in revised form: 24-08-2023
Accepted: 27-08-2023
Available online: 30-09-2023

Keywords:

Antimicrobial Resistance; Drug-Resistant Bacteria; Molecular Drills; Nanomachines; Nanotechnology.

ABSTRACT

The emergence of drug-resistant bacteria poses a significant threat to global health, necessitating innovative approaches to treatment. Nanomachines, designed to target and neutralise pathogenic bacteria, represent a cutting-edge solution. These molecular machines operate at nanoscale dimensions and employ mechanisms such as mechanical drilling and targeted delivery to disrupt bacterial cell membranes. This review explores the principles, design intricacies, mechanisms, applications, and potential challenges of nanomachines in combating drug-resistant infections, with an emphasis on recent advancements and future prospects. These advancements underline the importance of integrating nanotechnology into modern antimicrobial strategies to address the escalating crisis of antimicrobial resistance.

DOI: https://doi.org/10.54368/qijirse.2.3.0003

1.0 INTRODUCTION

AMR is becoming a global health threat; it is the cause of a significant risk to global public health and economic stability. According to projections, if no effective measures are taken, drug-resistant infections will lead to more than 10 million deaths worldwide by 2050 and will surpass cancer and diabetes mortality rates (Ruban *et al.,* 2020). Multidrug-resistant pathogens, such as Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae, sent an alarm through the medical community due to their ability to avoid treatments. The pathogens render a lot of conventional antibiotics useless, which often prolongs illness, increases mortality, and increases costs for healthcare systems. This has not only spread antimicrobial resistance across all geographic

* *Corresponding author's e-mail:* rubanbiotechz@gmail.com (Ruban P)

regions but also threatened the safety of standard medical treatments that include surgeries, organ transplantations, and chemotherapy from untreatable infections, challenging the broader system of medicine.

The various root causes behind AMR are diversified: firstly, from the overuse and abuse of antibiotics in human health, and secondly, its further application in agriculture. This indiscriminate use accelerates the natural selection of resistant strains, causing "superbugs" that are resistant to conventional therapies (Ventola, 2015). In some cases, poor diagnostic technologies for early infections mean treatments are delayed or not started at all. It just makes matters worse. Not helping is that antibiotic drugs have been in slow motion, failing to catch pace with the swift bacterial mutation mechanisms. The financial and scientific challenges of developing new antibiotics leave little investment from pharmaceuticals and thus widen the gap further, opening options for effective treatments (Nathan & Cars, 2014).

Bacteria have developed high-level resistance strategies, including antibiotic-degrading enzymes like beta-lactamases, efflux pumps to pump out drugs, and biofilm formation that protects bacterial communities from outside threats (Hancock, 2015). The development of these adaptive mechanisms demands creative solutions against AMR. This means that alterations in existing drugs or combined drugs are merely useful and demand change through novel therapy regimes.

Nanotechnology is an inspiring revolution for handling AMR issues. Providing nanoscale devices with precise biological interactions gives nanotechnology tools that can surpass the limitations of conventional antibiotics. From all of them, nanomachines stand tall. It will revolutionise the way infections are managed. As molecular-scale devices, one can even engineer at the molecular scale to affect targeted functions such as bacterial membrane disruptions, high-specificity drug delivery, and penetration of biofilms that could not be affected by conventional antibiotics penetration (Saha *et al.,* 2019). Nanomachines will also allow one to fine-tune immune responses or even enhance the efficacy of antibiotics known so far around traditional resistance pathways.

Although these advances seem rather promising, nanomachine implementations in clinical practice pose some problems, such as toxicity, biocompatibility, and scale-up; thus, they should be controlled for safety and efficiency. The fourth problem is that high solutions based on nanotechnology would mean a cost that would become insurmountable, especially in low- and middle-income countries (Zhou *et al.,* 2021). More critical review must be carried out in terms of the regulatory frameworks and ethical issues to ensure that nanomachines become accepted in mainstream medicine.

Research is still ongoing to unravel the possibility of tailoring nanomachines to counter specific resistant pathogens. It has shown potential for targeting MDR strains with minimal off-target effects, which has provided a framework for further innovations (Wang *et al.,* 2020). It is, therefore, imperative that the gap between microbiologists, materials scientists, and clinicians be bridged through interdisciplinary collaboration to unlock the full potential of nanotechnology in combating AMR. This would speed up the development and deployment of nanomachines and revolutionise the landscape of antimicrobial therapeutics against one of the most challenging health problems of our time.

2.0 DESIGN AND MECHANISM OF ACTION

Targeted bacteria nanomachines are designed to be highly specific and efficient. These advanced nanoscale devices work according to a variety of innovative mechanisms specifically designed to attack bacterial infections with minimal damage to the surroundings. Due to their multifunctionality and precision, they have emerged as innovative tools against antibiotic-resistant bacteria and persistent infections.

The most innovative design of nanomachines is mechanical drilling. Molecular drills work on external stimuli such as light, ultrasound or chemical energy. It allows it to penetrate bacterial cell membranes physically. The mechanical action itself disrupts the integrity of the bacterial cell wall and causes irreversible damage, leading to the death of the bacterial cell. Such precision targeting minimises harm to surrounding healthy cells. For example, molecular drills have been demonstrated by Smith *et al.* (2021) to selectively deliver and lyse Staphylococcus aureus cells, which can be considered a massive approach toward combating bacterial resistance. In addition, their study proved the potential for modification towards different strains of bacteria in order to be compatible with various clinical requirements.

Another application of nanomachines is the targeted delivery of drugs. These nanomachines are designed in such a way that they carry antimicrobial agents for direct delivery to bacterial cells. Molecular recognition elements like ligands or antibodies in nanomachines are used in high-precision drug delivery by molecular recognition, thus showing high accuracy in the drug delivery mechanism. It also increases local concentrations at the site of infection while decreasing systemic toxicity and adverse effects. For instance, Lee *et al.* (2019) designed delivery systems to reduce the bacterial load that was substantially retained in the viable tissues. Their work then paved a new approach to personalised antimicrobial therapy whereby treatment would be tailored towards what an individual patient required.

This community of bacteria, highly structured, is embedded within an extracellular matrix that is self-generated. This has afforded them a form of immunity against conventional antibiotics. As for nanomachines, this problem was overcome with its design that added enhanced mobility, surface modification, and enzymatic functionality. Therefore, the device can pierce the biofilm to break down the protective matrix and deliver the therapeutic agents directly to the bacterial colonies. According to Kumar *et al.* (2022), nanomachine technology has achieved considerable advancements in the disruption of biofilm. The research observed that nanomachines incorporated with matrix-degrading enzymes can degrade biofilms and restore antibiotic efficacy. Such developments are essential for chronic infection control and in diminishing the rate of re-occurrence.

In addition, nanomachines can be used to perform diagnostics and perform real-time infection monitoring. Biosensors loaded inside nanomachines improve the detection of the existence and activities of bacteria, which are significant factors in treatment decisions. A few examples are works such as those recently introduced by Zhang *et al.* (2023), revealing nanomachines with capabilities as theranostic: they can serve and perform both therapeutic and diagnosis-related purposes. Such machines, aside from killing invading bacteria, also provide indications for the effectiveness of treatments done on the patient, further ensuring that control measures for infections will involve comprehensive management.

3.0 APPLICATIONS IN COMBATING DRUG-RESISTANT BACTERIA

Nosocomial infections, an important issue in health care today, are especially of concern for multidrug-resistant (MDR) bacteria, such as Acinetobacter baumannii and Pseudomonas aeruginosa. Such pathogens quickly become resistant to a multitude of antibiotics, making these infections very hard to treat. A nanoscale machine may be utilised to target these bacteria. These agents can be designed to have their effects directly on the bacterial cells, either by breaking their membrane or by delivering potent antimicrobial agents to the sites of infection. Many further complicating factors are provided when one discusses a hospital environment in terms of bacterial infections, such as biofilms that consist of communities of bacteria enclosed by a protective layer that hardens the treatment of infections caused by them with conventional antibiotics. Nanomachines have exhibited an ability to penetrate these biofilms, break them down and render the bacteria more sensitive to treatment. Research has been done by Johnson *et al.* (2021) on the applications of nanomachines; the nanomachines disrupt biofilms and prevent their reformation, thereby lessening the bacterial load inside hospitals. This will not only treat infections but also enhance infection control practices, reducing the rates of nosocomial infections and enhancing the patient's outcome.

3.1 Chronic Wound Healing

Biofilm-producing MDR bacteria are generally isolated to infect chronic wounds like diabetic ulcers, pressure sores, and venous leg ulcers. Such infections are often difficult to treat because the bacteria in biofilms are protected from the host's immune response as well as antibiotics. It has generally failed to treat the wound with conventional treatments and antibiotic therapy, leading to delayed healing and increased systemic infection complications. Nanomachines have proven to be a breakthrough in wound care with localised and sustained antibacterial activity at the wound site. Nanomachines can be implanted within advanced wound dressings. Nanomachines work to remove bacteria, break up biofilms, and stimulate tissue regeneration at the wound site. Nanomachines target bacteria directly, and this helps not only treat the infection but also heal faster. Results shown by Patel *et al.* (2023) prove that dressings incorporating nanotechnology promote wound healing in animal models, which has considerable implications for treating patients. The main advantage of controlling and delivering the release of an antimicrobial under conditions at the site of a wound is having low-dose antibiotics applied, which thereby eliminates the possibility of acquiring further resistance to antibiotics, especially for patients acquiring chronic diseases such as diabetes. These conditions typically delay the healing of the wounds and often infect the wounds.

3.2 Sepsis Management

Sepsis is essentially a disease caused by the infection of a part. It usually results from any infection leading to the full-blown inflammatory response of an entire body system, leading sometimes to the failure of various organs and eventual death. Perhaps due to its nature, which usually involves fast progression involving antibiotic-resistant bacteria, sepsis has proved particularly hard to treat. Bacterial toxins, along with pathogens, spread across all parts of the bloodstream due to systemic inflammation in sepsis. Nanomachines can potentially mitigate this process. Nanomachines can be injected into the blood and can actively target bacterial toxins, neutralise these toxins and remove the pathogens from the blood, which modulates the immune system and prevents the overwhelming inflammatory response characteristic of sepsis. According to the experiments with models mentioned by Ruban *et al.* (2020), nanomachines successfully minimised mortality while dealing with sepsis in terms of its bacterial infection and subsequent inflammatory damage. These machines eliminate endotoxins—compounds from bacteria and cause a breakdown in processes, which creates a cascade effect that ends in dysfunction in organs. The result is a significant improvement in survival rates and also a reduction in complications related to sepsis, thus providing a new avenue for managing this critical and often fatal condition.

3.3 The Promise and Future Directions of Nanomachines

Nanomachines are yet in the introductory stage of application in the clinic, with clear potential for revolution in the treatment of drug-resistant infections. It is even possible that they will gradually be used within a considerable range of medical applications--from infection control in a hospital to personalised treatments for chronic infections. Future research may be aimed at nanomachines' specificity by targeting a specific kind of bacteria. This means that off-target effects would be minimal. They are also being made biocompatible, meaning they are safe for human use. One promising direction is that they are integrated with diagnostic tools, which can then monitor infections in real time and tailor treatments based on the type of pathogen. As these technologies continue to evolve, they may reduce the use of antibiotics and limit the proliferation of drug-resistant bacteria, which are increasingly becoming a global threat.

4.0 CHALLENGES AND FUTURE DIRECTIONS

Despite the tremendous medical potential of nanomachines, there are many challenges that their application needs to overcome for use on a broader scale. Some of these challenges follow, and efforts are being made to overcome them.

4.1 Biocompatibility and Safety

One of the most significant problems in the clinical application of nanomachines is their biocompatibility, which should not trigger adverse immune responses or be toxic to human tissues. Nanomachines are fabricated from materials that may be perceived as foreign to the body, thus being harmful to the immune system and triggering inflammation, allergic reactions, or even damage to organs. Additionally, because nanomachines work at a nanoscale, they can accumulate in tissue or organs, which causes fear about the long-term adverse health impacts.

Researchers are working on developing highly biocompatible materials, which have very low immunogenicity- the ability to provoke an immune response. Some examples include biocompatible polymers, compounds based on silica, and functionalised surfaces with excellent interaction properties with the biological system. Surface modifications can be significant because it is possible to design a surface that reduces the probabilities of immune system activation, thus improving the biocompatibility of nanomachines. According to Yang *et al.* (2021), surface modification of nanomachines is critical in order not to trigger an immune reaction or toxicity. Optimising the materials and design will help create nanomachines that can be safely navigated through the body without causing harm, thus paving the way for their use in clinical settings.

4.2 Scalability and Cost

The prospects of nanomachines are massive, but the problem is that manufacturing them poses a huge challenge. They require nanoscale molecular assembly, precision engineering and integration of different materials, which are elaborate and time-consuming processes, hence making large-scale production extremely expensive. As a result, despite the promising applications of nanomachines, their widespread clinical use could be limited by the high cost of production.

It has also attempted accessibility by standardising more of the methods well while reducing production costs. They are making research about a new material cheap so it will not lose any strength used in the fabrication of a nanomachine during construction. For instance, Chen *et al.* (2022) have proposed new production techniques that can be applied in manufacturing processes by adopting less complex modes of manufacturing or more readily available, cheaper materials. Moreover, advancements in automation and scalable production techniques will allow for the mass production of nanomachines. Cost-effectiveness will be a challenge to make these technologies more accessible on a larger scale, as well as integrate them into healthcare systems worldwide, especially in resource-poor settings.

4.3 Regulatory Barriers

The regulatory landscape of nanomachines is still very preliminary and, at best, challenging when it comes to the standardisation of the approval processes as well as proper guidelines on their use in clinical practice. Nanomachines are very different from conventional drugs or medical devices, and therefore, their design, functionality, and interactions with biological systems pose several novel challenges. Because of their novelty, there are very few established protocols for testing their safety and efficacy, and regulatory agencies are still working to establish frameworks that can address these concerns effectively.

Critical: The broad preclinical testing and safety evaluation in establishing that nanomachines do not present a hazard to human subjects will include toxicity, long-term effects, and unforeseen side effects in the body. With such variables, regulatory agencies must develop flexible guidelines for varying types of nanomachines. According to the study by Ruban *et al.* (2020), multidisciplinary collaboration of scientists, clinicians, and regulatory authorities can overcome these obstacles. Through this, these stakeholders will be in a position to come up with more stringent and efficient testing, approval, and clinical implementation protocols for nanomachines to ensure safe use in healthcare.

4.4 Ethical and Social Considerations

Apart from technical challenges, the clinical application of nanomachines raises very important questions of ethics and society. *For example,* how would one explain the long-term effect of introducing nanomachines into a human body—the possibility of an undesirable biological consequence or an ecological impact if these devices happen to enter the environment? Concerns over privacy, data security, and access to high-tech healthcare also arise, especially where nanomachines can be used for personalised medicine or real-time monitoring.

A critical issue to be addressed will be access to these technologies-equality issues-and may potentially result in limited access to such nanomachines, as it is expensive to manufacture them and thus limit their availability among specific populations or regions. All these issues of nanotechnology would require careful consideration while matching them with technical and regulatory ones for the proper realisation of its benefits to be considered both safe and just among people.

5.0 CONCLUSION

Nanomachines targeting drug-resistant bacteria: a disruptive innovation against AMR. These devices fill a critical gap within existing antimicrobial therapies because they take advantage of the nanoscale precision and sophisticated mechanisms. However, the translation of technology from lab to clinical practice mainly involves overcoming challenges related to safety, scalability, and regulatory frameworks. This will depend on further research, interdisciplinary collaborations and strategic investment and will unlock the full potential of nanomachines to win the battle against the most resistant infections and continue to fight the war on AMR.

REFERENCES

Chen, Y., Li, L., Zhang, T., & Wang, S. (2022). Overcoming scalability challenges in the production of nanomachines for medical applications. *Nature Nanotechnology, 17*(2), 98-106.

Hancock, R. E. (2015). Mechanisms of action of newer antibiotics. *Antimicrobial Agents and Chemotherapy, 59*(11), 6887-6896.

Johnson, C. E., Chen, L., & Smith, R. G. (2021). Nanomachines in hospital infection control: Addressing nosocomial infections and biofilm disruption. *Journal of Hospital Infection, 115*(3), 223-230.

Kumar, P., Singh, R., & Patel, S. (2022). Nanomachines for biofilm disruption and chronic infection control: Advances and prospects. *Journal of Nanomedicine and Nanotechnology, 13*(5), 251-261.

Lee, J. S., Zhang, D., & Lin, L. (2019). Targeted drug delivery with nanomachines: The future of personalised antimicrobial therapy. *International Journal of Nanomedicine, 14*, 1841-1853.

Nathan, C., & Cars, O. (2014). Antibiotic resistance—Problems, progress, and prospects. *New England Journal of Medicine, 371*(19), 1761-1763.

Patel, D., Desai, H., & Lee, J. Y. (2023). Nanotechnology in wound care: Advances in the treatment of chronic diabetic ulcers. *Journal of Diabetes Research,* 1248356.

Ruban, S., Santos, M. J., & Patel, N. (2020). Bridging the gap: Regulatory and ethical challenges in nanomachines for antimicrobial resistance. *Bioengineering & Translational Medicine, 5*(3), e10191.

Saha, S., Patra, H. K., & Das, S. (2019). Nanomachines in combating drug-resistant bacteria: Nanoscale devices for precise targeting and biofilm penetration. *Journal of Nanoscience and Nanotechnology, 19*(4), 2059-2067.

Smith, R. G., Anderson, M., & Williams, D. (2021). Molecular drills: Nanomachines for bacterial cell wall disruption. *Nanotechnology Research Journal, 8*(7), 123-134.

Ventola, C. L. (2015). The Antibiotic Resistance Crisis: Part 1: Causes and Threats. *Pharmacy and Therapeutics*, *40*(4), 277. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/

Wang, X., Zhang, Z., & Liu, H. (2020). Tailoring nanomachines for combating multidrug-resistant pathogens: The future of targeted therapies. *Nature Reviews Microbiology, 18*(5), 286-297.

Yang, M., Zhang, Q., & Lee, C. J. (2021). Biocompatibility of nanomachines: The importance of surface modifications. *Nanomaterials, 11*(12), 3131.

Zhang, L., Li, P., & Wu, J. (2023). Theranostic nanomachines: Dual therapeutic and diagnostic functions in bacterial infections. *Advanced Drug Delivery Reviews, 181*, 114016.

Zhou, J., Li, X., & Zhang, F. (2021). Overcoming the cost challenges of nanotechnology in global health: Toward affordable solutions. *Lancet Infectious Diseases, 21*(4), 497-504.